GlassScriptPhysician profile
Carlos Hernandez-Cassis
NPI 1952366197
$2,813.05
in general payments reported to CMS, 2019-2025
33 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $16.04 · 2021: $725 · 2022: $790 · 2023: $151 · 2024: $717 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122 · Education: $27.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.91 |
| Education | $27.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.62 | 2021-2023 | Ozempic, Rybelsus |
| Corcept Therapeutics | $340.14 | 2021-2024 | Korlym |
| Chiesi USA, INC. | $206.38 | 2024 | Myalept |
| Insulet Corporation | $168.51 | 2021-2022 | |
| Lilly USA, LLC | $160.59 | 2022-2023 | Mounjaro |
| Abbvie INC. | $157.86 | 2019-2021 | |
| Radius Health, INC. | $150.51 | 2022-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $145.22 | 2021-2024 | |
| Ascendis Pharma Endocrinology INC | $142.92 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $129.64 | 2022-2024 | |
| Madrigal Pharmaceuticals | $124.99 | 2024 | Resmetirom |
| Dexcom, INC. | $116.89 | 2021-2022 | |
| Averitas Pharma INC. | $67.94 | 2023-2024 | Qutenza |
| Recordati_rare_diseases_inc. | $49.55 | 2023-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $39.28 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $36.53 | 2022-2023 | Tepezza |
| Amgen INC. | $34.75 | 2025 | Tepezza |
| Scilex Pharmaceuticals INC. | $34.66 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $34.39 | 2023 | Quviviq |
| Tersera Therapeutics LLC | $28.91 | 2022 | |
| Appliedvr INC | $21.76 | 2025 | Relievrx |
| Abbott Laboratories | $21.12 | 2021 | |
| Ionis Pharmaceuticals, INC. | $20.87 | 2025 | Tryngolza |
| Boston Scientific Corporation | $20.59 | 2025 | General - Pain Management |
| Kowa Pharmaceuticals America, INC. | $19.58 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.43 | 2024 | Recorlev |
| Saluda Medical Americas, INC. | $18.26 | 2024 | Evoke |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.51 | 2025 | Jardiance |
| Biodelivery Sciences International, INC. | $16.04 | 2020 | |
| Zyla Life Sciences, INC. | $15.64 | 2019 | |
| Grt US Holding, INC. | $5.97 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Hernandez-Cassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.